---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-024139"
form_type: "8-K"
ticker: "LRMR"
cik: "0001374690"
company_name: "Larimar Therapeutics, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T22:34:09.387750+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Larimar Q3 net loss narrows to $8.3M; Phase 2 CTI-1601 trial resumes with data expected 2H 2023

## Summary
- Net loss $8.3M ($0.37/share) in Q3 2022 vs $16.8M ($0.92) in Q3 2021; 9-month net loss $25.9M ($1.32) vs $41.5M ($2.48).
- Cash and marketable securities $124.7M at Sept 30, providing projected cash runway into 2H 2024.
- FDA lifted full clinical hold; Phase 2 25 mg dose exploration cohort in Friedreich's ataxia patients is ongoing; top-line data expected 2H 2023.
- Net proceeds of ~$75.2M raised in September 2022 underwritten offering; Deerfield Management participated.
- U.S. Patent No. 11,459,363 issued for CTI-1601 composition of matter, covering into July 2040.

## SEC filing metadata
- accession: 0000950170-22-024139
- form_type: 8-K
- ticker: LRMR
- cik: 0001374690
- company_name: Larimar Therapeutics, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374690/000095017022024139/0000950170-22-024139-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374690/000095017022024139/lrmr-20221110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-024139
- JSON: https://secwatch.observer/filing/0000950170-22-024139.json
- Plain text: https://secwatch.observer/filing/0000950170-22-024139.txt

## Key facts
- Earnings Releases
  Larimar Therapeutics, Inc. reported the nine months ended September 30, 2022 results: net income a net loss for the nine months ended September 30, 2022 of $25.9 million, or $1.32 per share, EPS $1.32 per share.
  - Period: the nine months ended September 30, 2022
  - Net income: a net loss for the nine months ended September 30, 2022 of $25.9 million, or $1.32 per share
  - EPS: $1.32 per share
  - Result: reported results
  source text: The Company reported a net loss for the nine months ended September 30, 2022 of $25.9 million, or $1.32 per share, compared to a net loss of $41.5 million, or $2.48 per share, for the nine months ended September 30, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1374690/000095017022024139/0000950170-22-024139-index.htm
- Earnings Releases
  Larimar Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: net income a net loss for the third quarter of 2022 of $8.3 million, or $0.37 per share, EPS $0.37 per share.
  - Period: the third quarter ended September 30, 2022
  - Net income: a net loss for the third quarter of 2022 of $8.3 million, or $0.37 per share
  - EPS: $0.37 per share
  - Result: reported results
  source text: The Company reported a net loss for the third quarter of 2022 of $8.3 million, or $0.37 per share, compared to a net loss of $16.8 million, or $0.92 per share, for the third quarter of 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1374690/000095017022024139/0000950170-22-024139-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.